XML 35 R19.htm IDEA: XBRL DOCUMENT
v3.20.4

Mezzanine and Stockholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2020
Stockholders' Equity Note [Abstract] |
Mezzanine and Stockholders’ Equity | Mezzanine and Stockholders’ Equity APC As the redemption feature (see Note 2) of APC's shares of common stock is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interests in mezzanine or temporary equity. APC’s shares were not redeemable and it was not probable that the shares would become redeemable as of December 31, 2020, 2019 and 2018. On September 10, 2019, APC-LSMA, a holding company of APC, acquired 100% of the aggregate issued and outstanding shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock. On September 11, 2019, AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. This investment was eliminated in consolidation. In relation to the issuance of APC Series A Preferred Stock, APC incurred $0.9 million in cost (see Note 1). Stockholders’ Equity Preferred Stock – Series A In October 2015, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 1,111,111 units, each unit consisting of one share of ApolloMed’s Series A Preferred Stock and a common stock warrant to purchase one share of ApolloMed’s common stock at an exercise price of $9.00 per share. NMM paid ApolloMed an aggregate of $10.0 million for the units. Preferred Stock – Series B In March 2016, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 555,555 units, each unit consisting of one share of ApolloMed’s Series B Preferred Stock and a common stock warrant to purchase one share of ApolloMed’s common stock at an exercise price of $10.00 per share. NMM paid ApolloMed an aggregate $5.0 million for the units. 2017 Share Issuances and Repurchases In December 2017, ApolloMed completed its business combination with NMM following the satisfaction or waiver of the conditions set forth in the Merger Agreement, pursuant to which Merger Subsidiary merged with and into NMM, with NMM surviving as a wholly owned subsidiary of ApolloMed. In connection with the 2017 Merger and as of the effective time of the Merger (the “Effective Time”): •each issued and outstanding share of NMM common stock was converted into the right to receive such number of shares of common stock of ApolloMed that results in the former NMM shareholders who did not dissent from the 2017 Merger (“former NMM Shareholders”) having a right to receive an aggregate of 30,397,489 shares of common stock of ApolloMed, subject to the 10% holdback pursuant to the Merger Agreement; •ApolloMed issued to former NMM Shareholders each former NMM Shareholder’s pro rata portion of (i) warrants to purchase an aggregate of 850,000 shares of common stock of ApolloMed, exercisable at $11.00 per share, and (ii) warrants to purchase an aggregate of 900,000 shares of common stock of ApolloMed, exercisable at $10.00 per share; and •ApolloMed held back an aggregate of 3,039,749 shares of common stock issuable to former NMM Shareholders, representing 10% of the total number of shares of ApolloMed common stock issuable to former NMM Shareholders, to secure indemnification rights of AMEH and its affiliates under the Merger Agreement (the “Holdback Shares”). The Holdback Shares were issued and outstanding as of December 31, 2020. The first tranche of 1,519,805 shares were issued in December 2018 and the remaining 1,511,380 were issued in December 2019, net of shares repurchase. The shares of common stock issuable to former NMM shareholders in the exchange were 25,675,630 (net of 10% holdback and Treasury Shares). The 10% holdback shares will be released to all the former NMM shareholders based on their respective pro rata ownership interest in NMM at the Effective Time without regard to whether the former NMM shareholders are providing any services to the Company at the time of this distribution. This holdback accommodation was made as indemnification protection to the accounting acquiree (ApolloMed), and as such, is not considered compensatory. At the time when these holdback shares were issued to the former NMM shareholders, the Company recorded the stock issuance with a reduction to additional paid-in capital to properly reflect the shares outstanding. Upon consummation of the 2017 Merger, the Company issued 520,081 shares of its common stock with a fair value of approximately $5.4 million from the conversion of a convertible promissory note issued by the Company in 2017. Common Stock As of December 31, 2020, 276,038 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the Merger. Warrants Common stock warrants, to purchase 1,111,111 shares of ApolloMed common stock, issued to NMM in connection with the Series A Preferred Stock investment in ApolloMed may be exercised at any time after issuance and through March 30, 2021, for $9.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro-rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the merger date. Common stock warrants, to purchase 555,555 shares of ApolloMed common stock, issued to NMM in connection with the Series B Preferred Stock investment in ApolloMed may be exercised at any time after issuance and through March 30, 2021, for $10.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro-rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the Merger date. The Company’s outstanding warrants consisted of the following:
| Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value (in millions)
Warrants outstanding at January 1, 2018 | 3,648,541 |  |  | $ | 9.75 |  |  | 3.74 |  | $ | 52.0 |
Warrants exercised | (286,357) |  |  | 7.84 |  |  |  |  | 3.0 |
Warrants forfeited | (30,189) |  |  | 4.50 |  |  |  |  | — |
Warrants outstanding at December 31, 2018 | 3,331,995 |  |  | $ | 9.93 |  |  | 2.97 |  | 33.1 |
Warrants granted | — |  |  | — |  |  | — |  |  | — |
Warrants exercised | (177,405) |  |  | 9.32 |  |  | — |  |  | 1.6 |
Warrants forfeited | — |  |  |  |  | — |  |  | — |
Warrants outstanding at December 31, 2019 | 3,154,590 |  |  | $ | 9.96 |  |  | 2.01 |  | 26.7 |
Warrants granted | — |  |  | — |  |  | — |  |  | — |
Warrants exercised | (1,247,644) |  |  | 9.33 |  |  | — |  |  | 9.8 |
Warrants forfeited | (28,820) |  |  | 9.00 |  |  | — |  |  | — |
Warrants outstanding at December 31, 2020 | 1,878,126 |  |  | $ | 10.39 |  |  | 1.63 |  | $ | 14.8 |
Exercise Price Per Share |  | Warrants Outstanding |  | Weighted Average Remaining Contractual Life |  | Warrants Exercisable |  | Weighted Average Exercise Price Per Share
$ | 9.00 |  |  | 10,810 |  |  | 0.24 |  | 10,810 |  |  | $ | 9.00 |
10.00 |  |  | 1,115,342 |  |  | 1.44 |  | 1,115,342 |  |  | 10.00 |
11.00 |  |  | 751,974 |  |  | 1.93 |  | 751,974 |  |  | 11.00 |
$9.00 – $11.00 |  | 1,878,126 |  |  | 1.63 |  | 1,878,126 |  |  | $ | 10.39 |
During the years ended December 31, 2020 and 2019, common stock warrants were exercised for 1,247,644 and 177,405 shares of the Company’s common stock, respectively which resulted in proceeds of approximately $10.5 million and $1.7 million, respectively. The exercise price ranged from $9.00 to $11.00 per share during year ended December 31, 2020 and December 31, 2019. Dividends During the years ended December 31, 2020, 2019 and 2018, NMM paid dividends of $0, $0 and $13.8 million, respectively. The dividends paid in the year ended December 31, 2019 were declared in December 2018 as part of the merger between ApolloMed and NMM and was classified as restricted cash (see Note 3). During the years ended December 31, 2020, 2019 and 2018, APC paid dividends of $136.6 million, $60.0 million and $2.0 million, respectively. During the years ended December 31, 2020, 2019 and 2018, CDSC paid distributions of $2.1 million, $2.6 million and $2.0 million, respectively. Treasury Stock APC owned 12,323,164 shares of ApolloMed's common stock as of December 31, 2020, and 17,290,317 shares of ApolloMed’s common stock as of December 31, 2019, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1). During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board, of which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of December 31, 2020 and 2019, the brokerage account only held shares of ApolloMed, as such the brokerage account totaling $7.7 million and $7.3 million, respectively, have been recorded as treasury shares.

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration